1 BTC
=
- USD
CorMedix Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Market Statistics
Trading Metrics
How to Buy CRMD
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CRMD
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCorMedix is experiencing strong commercial momentum with its DefenCath catheter lock solution, which has shown a 72% reduction in catheter-related bloodstream infections in real-world evidence studies. The company reported Q3 2025 net revenue of $104.3 million and raised full-year guidance to $390-410 million. DefenCath adoption is outpacing expectations, and the Melinta Therapeutics acquisition adds diversification. Analysts are optimistic with nearly-unanimous Buy ratings and see 48% upside potential, though risks include pricing pressure and pipeline concentration.
CorMedix completed enrollment in a Phase III clinical trial for REZZAYO, a drug aimed at preventing fungal infections in patients undergoing blood and marrow transplantation. Topline results are expected in Q2 2026, with potential FDA approval for prophylaxis treatment.
CorMedix has successfully acquired Melinta Therapeutics for $300 million, expanding its commercial product portfolio with seven innovative drug products and raising financial guidance to $325-$350 million in pro forma 2025 revenues.